<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00580320</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-03740</org_study_id>
    <nct_id>NCT00580320</nct_id>
  </id_info>
  <brief_title>Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma</brief_title>
  <official_title>Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bortezomib will enhance the activity of dacarbazine against melanoma and soft tissue sarcoma.&#xD;
      Weekly administration of the combination will prove to be feasible and tolerable at an&#xD;
      appropriate dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to determine recommended phase II doses for the combination&#xD;
      dacarbazine and bortezomib administered weekly.&#xD;
&#xD;
      Secondary objectives are to determine the maximum tolerated dose combination and to observe&#xD;
      anti-tumor activity in terms of response rate(s), duration of response, time to progression,&#xD;
      and time on treatment (a measure of both antitumor activity and treatment tolerance).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by serious adverse events</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Melanoma</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Parathyroid Carcinoma</condition>
  <condition>Small Cell Carcinoma of the Lung</condition>
  <condition>Carcinoid Tumors</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dacarbazine + bortezomib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine and bortezomib</intervention_name>
    <description>Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2</description>
    <arm_group_label>A</arm_group_label>
    <other_name>bortezomib (velcade)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of cutaneous or mucosal melanoma, soft tissue sarcoma (STS), or&#xD;
             an APUD (amine precursor uptake and decarboxylation) tumor. APUD tumors include&#xD;
             parathyroid carcinoma, medullary carcinoma of the thyroid, small cell carcinoma of the&#xD;
             lung, pheochromocytoma, islet cell tumors, carcinoid tumors, and malignant&#xD;
             paraganglioma.&#xD;
&#xD;
          -  Measurable or evaluable disease not appropriate for resection and/or radiation with&#xD;
             curative intent. Patients with small cell carcinoma must have extended stage disease&#xD;
             or, if limited stage disease, must have received at least one prior systemic therapy.&#xD;
&#xD;
          -  Age 18 years or greater&#xD;
&#xD;
          -  ECOG Performance Status 0 or 1&#xD;
&#xD;
          -  Women must be post-menopausal, infertile as the result of a surgical procedure, or&#xD;
             willing to use a medically accepted form of birth control (abstinence, hormonal&#xD;
             contraceptive, intra-uterine device, diaphragm with spermicide, condon with&#xD;
             spermicide) for the duration of study treatment. Men also must agree to use a&#xD;
             medically accepted form of birth control for the duration of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled brain metastatic disease&#xD;
&#xD;
          -  Platelet count &lt;100&#xD;
&#xD;
          -  Absolute neutrophil count &lt;1.5&#xD;
&#xD;
          -  Blood transfusion or hematopoietic growth factors for cytopenia within one month of&#xD;
             enrollment.&#xD;
&#xD;
          -  Calculated or measured (Cockcroft and Gault formula) creatinine clearance &lt;30&#xD;
             mL/minute&#xD;
&#xD;
          -  AST &gt; 3 times the upper limit of normal, unless elevation due to metastatic disease,&#xD;
             in which case AST &gt; 5 times the upper limit of normal&#xD;
&#xD;
          -  Bilirubin &gt; 2 mg/mL&#xD;
&#xD;
          -  Grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  Hypersensitivity to bortezomib, boron, mannitol, or dacarbazine&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Other investigational drugs within 14 days of enrollment&#xD;
&#xD;
          -  Other medical or other condition(s) that in the opinion of the&#xD;
             investigator/sub-investigator might compromise the objectives of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Poklepovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massey Cancer Center/Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618599/</url>
    <description>Publication</description>
  </link>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>APUD tumor</keyword>
  <keyword>dacarbazine</keyword>
  <keyword>bortezomib</keyword>
  <keyword>velcade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Parathyroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

